JP2019504631A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019504631A5 JP2019504631A5 JP2018541222A JP2018541222A JP2019504631A5 JP 2019504631 A5 JP2019504631 A5 JP 2019504631A5 JP 2018541222 A JP2018541222 A JP 2018541222A JP 2018541222 A JP2018541222 A JP 2018541222A JP 2019504631 A5 JP2019504631 A5 JP 2019504631A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- genetically modified
- immunocompetent
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291999P | 2016-02-05 | 2016-02-05 | |
| US62/291,999 | 2016-02-05 | ||
| PCT/US2017/016543 WO2017136748A1 (en) | 2016-02-05 | 2017-02-03 | Compositions and methods for recombinant cxadr expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019504631A JP2019504631A (ja) | 2019-02-21 |
| JP2019504631A5 true JP2019504631A5 (https=) | 2020-03-12 |
Family
ID=59500016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018541222A Abandoned JP2019504631A (ja) | 2016-02-05 | 2017-02-03 | 組換えｃｘａｄｒ発現のための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190046570A1 (https=) |
| EP (1) | EP3411474A4 (https=) |
| JP (1) | JP2019504631A (https=) |
| KR (1) | KR20180102108A (https=) |
| CN (1) | CN108884443A (https=) |
| AU (1) | AU2017214581A1 (https=) |
| CA (1) | CA3012472A1 (https=) |
| WO (1) | WO2017136748A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111727262A (zh) * | 2017-07-25 | 2020-09-29 | 加州理工学院 | 胞啃介导的表位发现 |
| CN109576231B (zh) * | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| EP4010496A4 (en) | 2019-08-09 | 2023-09-06 | Nantomics, LLC | Machine methods to determine neoepitope payload toxicity |
| CN119876018B (zh) * | 2024-12-16 | 2026-01-30 | 广东志珞生物科技有限公司 | 一种nk细胞及其在制备抗肿瘤药物中的用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994132A (en) * | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| AU2001237042A1 (en) * | 2000-02-16 | 2001-08-27 | University Of Massachusetts | Transgenic, non-human animals containing a coxsackie/adenovirus receptor (car) |
| JP2005523942A (ja) * | 2002-04-30 | 2005-08-11 | アヴィオル セラピューティクス インコーポレイテッド | 免疫療法のためのアデノウイルスベクター |
| EP3157958B1 (en) * | 2014-06-18 | 2020-05-06 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Car-expressing nk-92 cells as cell therapeutic agents |
-
2017
- 2017-02-03 JP JP2018541222A patent/JP2019504631A/ja not_active Abandoned
- 2017-02-03 WO PCT/US2017/016543 patent/WO2017136748A1/en not_active Ceased
- 2017-02-03 CN CN201780009615.2A patent/CN108884443A/zh not_active Withdrawn
- 2017-02-03 US US16/073,947 patent/US20190046570A1/en not_active Abandoned
- 2017-02-03 KR KR1020187022005A patent/KR20180102108A/ko not_active Withdrawn
- 2017-02-03 EP EP17748289.0A patent/EP3411474A4/en not_active Withdrawn
- 2017-02-03 CA CA3012472A patent/CA3012472A1/en not_active Abandoned
- 2017-02-03 AU AU2017214581A patent/AU2017214581A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tian et al. | Engineering strategies to enhance oncolytic viruses in cancer immunotherapy | |
| Heidbuechel et al. | Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies | |
| Jones et al. | Cell surface–tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy | |
| CN109862912B (zh) | 携带双特异性t细胞衔接器的腺病毒 | |
| Lanitis et al. | Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor | |
| Qiu et al. | Cytomegalovirus-based vaccine expressing a modified tumor antigen induces potent tumor-specific CD8+ T-cell response and protects mice from melanoma | |
| Vasconcelos et al. | Pathogen-induced proapoptotic phenotype and high CD95 (Fas) expression accompany a suboptimal CD8+ T-cell response: reversal by adenoviral vaccine | |
| JP2010527919A5 (https=) | ||
| JP2019504631A5 (https=) | ||
| CN115243700A (zh) | 治疗性细胞组合物及其制造方法和用途 | |
| Erkes et al. | Intratumoral infection with murine cytomegalovirus synergizes with PD-L1 blockade to clear melanoma lesions and induce long-term immunity | |
| Shen et al. | Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance | |
| US20200270574A1 (en) | CD1d and TCR-NKT Cells | |
| JP2024510712A (ja) | Ｉｌ－１５をコードするアデノウイルス | |
| US20230190922A1 (en) | Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer | |
| US20220195006A1 (en) | Peptide markers to track genetically engineered cells | |
| WO2023118508A1 (en) | Recombinant mva viruses for intraperitoneal administration for treating cancer | |
| JP2020524145A5 (https=) | ||
| JP2022512595A (ja) | 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法 | |
| JP2024038256A (ja) | 免疫応答を増強するための物質および方法 | |
| JP2023515471A (ja) | 抑制性キメラ受容体構造物 | |
| Liu et al. | Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models | |
| Ni et al. | Antitumor vaccination by Newcastle Disease Virus Hemagglutinin–Neuraminidase plasmid DNA application: Changes in tumor microenvironment and activation of innate anti-tumor immunity | |
| Han et al. | Target expression of Staphylococcus enterotoxin A from an oncolytic adenovirus suppresses mouse bladder tumor growth and recruits CD3+ T cell | |
| JP2020535832A (ja) | マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法 |